Metforal

Metformin Hydrochloride, the active ingredient in Metforal, is a biguanide presented as an oral tablet for oral use. It lowers hepatic glucose production and improves peripheral insulin sensitivity, making it a cornerstone therapy for adults with type 2 diabetes mellitus and for certain patients with impaired glucose tolerance.

GNH USA supplies Metforal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metforal (metformin hydrochloride) is used in the management of disorders related to glucose metabolism. - Type 2 diabetes mellitus: improves glycemic control by reducing fasting and post‑prandial glucose levels. - Prediabetes (impaired glucose tolerance): delays progression to overt diabetes when combined with lifestyle measures. - Polycystic ovary syndrome (PCOS): helps restore ovulatory cycles and reduce insulin resistance in women.

Metforal may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhoea. - Metallic taste: transient alteration of taste perception. - Weight loss: modest reduction in body weight.

Serious or Rare Side Effects: - Lactic acidosis: a rare but potentially fatal accumulation of lactate. - Severe hypoglycaemia: usually when combined with insulin or sulfonylureas. - Hepatotoxicity: abnormal liver enzymes indicating liver injury. - Vitamin B12 deficiency: long‑term use may reduce absorption.

When prescribing Metforal, clinicians should consider several safety precautions. - Renal function assessment: evaluate eGFR before initiation and periodically thereafter. - Contraindication in severe renal impairment: avoid use if eGFR <30 mL/min/1.73 m². - Monitor for lactic acidosis: watch for unexplained acidosis, especially after surgery or in hypoxic states. - Use with caution in hepatic disease: assess liver function because impaired clearance can increase risk. - Adjust dose in elderly patients: start at lower dose and titrate slowly. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Metforal can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure; discontinue metformin before and after imaging. - Cimetidine: increases metformin plasma concentrations, raising risk of lactic acidosis. - Alcohol excess: potentiates lactic acidosis risk.

Moderate Interactions (Monitor Closely): - Sulfonylureas or insulin: combined therapy can increase hypoglycaemia risk. - Diuretics (e.g., thiazides): may affect renal clearance of metformin. - Corticosteroids: can raise blood glucose, reducing metformin effectiveness. - ACE inhibitors or ARBs: monitor renal function as combined effect may affect kidney.